Company profile
MUSTANG BIO, INC.
NASDAQ:MBIOBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RELMAPIRAZIN | phase1_2 | — | 1 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05360238 | phase1_2 | terminated | 2022-05-24 | 2024-04-12 | Mustang Bio | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL |
| NCT04109482 | phase1_2 | terminated | 2020-02-17 | 2023-05-17 | Mustang Bio | Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. |
FDA applications (0)
No records yet.